{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:02:50Z","timestamp":1788436970098,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The \u201c100\u202fDays Mission\u201d (100DM), designed by the Coalition for Epidemic Preparedness Innovations (CEPI), represents an ambitious new concept in vaccine development for effective pandemic preparedness, rapid response, and the reduction of health inequalities. We aimed to identify potential obstacles to the success of the 100DM by conducting a survey among experts in vaccinology and public health from both high-income countries (HICs) and low- and middle-income countries (LMICs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A descriptive cross-sectional study was conducted, using a semi-structured online survey distributed to 116 experts from both LMICs and HICs. The data collected were analyzed quantitatively and qualitatively, highlighting the differences in responses between the LMICs and HICs respondents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate was 73.2% (85\/116), with 74% (57\/77) of the respondents from HICs and 69.2% (27\/39) from LMICs. The LMIC respondents (14\/27, 51.9%) were more confident in the success of the 100DM than the HIC respondents (15\/57, 26.3%). Additionally, LMIC respondents believed more strongly in the potential impact to overcome inequalities (15\/27, 55.6% vs. 19\/57, 33.3%). Almost all experts from both LMICs and HICs considered political will and governance, and sufficient sustainable funding as the most important prerequisites for the success of the 100DM, followed by the need for trustful collaborations between HICs and LMICs, effective public\u2013private partnership, and continuous training and capability building. The 100DM should prioritize the establishment of vaccine candidate libraries, enhancement and sustainability of surveillance capabilities, and creation of laboratory and clinical trial site networks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the first prospective survey evaluating the feasibility of 100DM, involving external stakeholders from both HICs and LMICs. Experts from LMICs are more confident in the success of the 100DM than those from HICs. Political will, good governance, and sustainable financing are essential for successful implementation. The technical innovation aspect of the 100DM should prioritize the development of prototype vaccines and operational components over more long-term initiatives with broader impacts. To realize CEPI\u2019s vision, global stakeholders must set priorities and commit to focused, coordinated actions. Achieving early wins through short-term, high-impact deliverables and actionable policy reforms is essential to build confidence, sustain momentum, and prevent stakeholder fatigue. This strategic prioritization underpins the initiative\u2019s long-term success.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1617066","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:41:30Z","timestamp":1757050890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pandemic preparedness and response: a survey among experts from high- and low-middle-income countries about the \u201c100 Days Mission\u201d"],"prefix":"10.3389","volume":"13","author":[{"given":"Vanessa","family":"Pencelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai Alexandru","family":"Bica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ann Costa","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"q2267","DOI":"10.1136\/bmj.q2267","article-title":"Pandemics are no longer \u201crare\u201d and now pose constant threat, global preparedness board warns","volume":"387","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"ref2","year":"2023"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cpt.1627","article-title":"Development times and approval success rates for drugs to treat infectious diseases","volume":"107","author":"DiMasi","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1056\/nejmp2202669","article-title":"Delivering pandemic vaccines in 100 days\u2014what will it take?","volume":"387","author":"Saville","year":"2022","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e221142","DOI":"10.3201\/eid2903.221142","article-title":"The 100 Days Mission\u20142022 global pandemic preparedness summit","volume":"29","author":"Gouglas","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"ref7","year":"2021"},{"key":"ref8","year":"2021"},{"key":"ref9","author":"Hatchett","year":"2022"},{"key":"ref10","year":"2022"},{"key":"ref11","author":"Vallance","year":"2021"},{"key":"ref12","author":"Vallance","year":"2021"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1016\/s2214-109x(24)00286-9","article-title":"Impact of the 100 Days Mission for vaccines on COVID-19: a mathematical modelling study","volume":"12","author":"Barnsley","year":"2024","journal-title":"Lancet Glob Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"102546","DOI":"10.1016\/j.tmaid.2023.102546","article-title":"What could drive the re-emergence of infectious diseases in a post-COVID19 era?","volume":"52","author":"Shapo","year":"2023","journal-title":"Travel Med Infect Dis"},{"key":"ref15","year":"2024"},{"key":"ref16","year":"2023"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1016\/j.vaccine.2022.06.054","article-title":"Vaccine innovation model: a technology transfer perspective in pandemic contexts","volume":"40","author":"Medeiros","year":"2022","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0002482","DOI":"10.1371\/journal.pgph.0002482","article-title":"Global regulatory reforms to promote equitable vaccine access in the next pandemic","volume":"3","author":"Mahoney","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","article-title":"The WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts","volume":"159","author":"Mehand","year":"2018","journal-title":"Antivir Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s43441-020-00154-y","article-title":"Evaluating the success of ZaZiBoNa, the southern African development community collaborative medicines registration initiative","volume":"54","author":"Sithole","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41541-023-00773-0","article-title":"Outlook of pandemic preparedness in a post-COVID-19 world","volume":"8","author":"Williams","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref22","year":""},{"key":"ref23","doi-asserted-by":"publisher","first-page":"101269","DOI":"10.1016\/j.eclinm.2021.101269","article-title":"The costs of improving health emergency preparedness: a systematic review and analysis of multi-country studies","volume":"44","author":"Clarke","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref24","year":""},{"key":"ref25","year":"2023"},{"key":"ref26","year":"2024"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/vaccines13070773","article-title":"100-day Mission for future pandemic vaccines, viewed through the Lens of low- and middle-income countries (LMICs)","volume":"13","author":"Hernandez-Ruiz","year":"2025","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41591-024-02939-2","article-title":"Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023","volume":"30","author":"Lazarus","year":"2024","journal-title":"Nat Med"},{"key":"ref29","year":"2022"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2450858","DOI":"10.1080\/21645515.2025.2450858","article-title":"Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: a cross-sectional study","volume":"21","author":"Comparcini","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"ref31","year":"2024"},{"key":"ref32","volume-title":"How to prevent the next pandemic","author":"Gates","year":"2022"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1617066\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:41:31Z","timestamp":1757050891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1617066\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":32,"alternative-id":["10.3389\/fpubh.2025.1617066"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1617066","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1617066"}}